Pembrolizumab Plus Pemetrexed and Platinum in Nonsquamous Non-Small-Cell Lung Cancer: 5-Year Outcomes From the Phase 3 KEYNOTE-189 Study

Authors

Marina C. Garassino
Shirish M. Gadgeel, Henry Ford HealthFollow
Giovanna Speranza
Enriqueta Felip
Emilio Esteban
Manuel Dómine
Maximilian J. Hochmair
Steven F. Powell
Helge G. Bischoff
Nir Peled
Francesco Grossi
Ross R. Jennens
Martin Reck
Rina Hui
Edward B. Garon
Takayasu Kurata
Jhanelle E. Gray
Paul Schwarzenberger
Erin Jensen
M. Catherine Pietanza
Delvys Rodríguez-Abreu

Recommended Citation

Garassino MC, Gadgeel S, Speranza G, Felip E, Esteban E, Dómine M, Hochmair MJ, Powell SF, Bischoff HG, Peled N, Grossi F, Jennens RR, Reck M, Hui R, Garon EB, Kurata T, Gray JE, Schwarzenberger P, Jensen E, Pietanza MC, and Rodríguez-Abreu D. Pembrolizumab Plus Pemetrexed and Platinum in Nonsquamous Non-Small-Cell Lung Cancer: 5-Year Outcomes From the Phase 3 KEYNOTE-189 Study. J Clin Oncol 2023.

Document Type

Article

Publication Date

2-21-2023

Publication Title

Journal of clinical oncology

PubMed ID

36809080

ePublication

ePub ahead of print

First Page

2201989

Last Page

2201989